Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 10 , ISSUE 2 ( May-August, 2021 ) > List of Articles


An Indian Perspective on the Use of Fluticasone/Formoterol in Asthma and Chronic Obstructive Pulmonary Disease Patients

Rahul Sharma, Zafar Ahmad Iqbal, Hemant Kalra, Abhinav Guliani, Anil K. Singh, Akshay Budhraja, Gaurav Jain, Bharat Mehrotra, Loveleen Mangla, Avi Kumar, Vinay Purohit, Monika Chinda

Keywords : Asthma, chronic obstructive pulmonary disease, dual fluticasone and formoterol, dual inhaled corticosteroid–long-acting beta2-agonist, inhaler

Citation Information : Sharma R, Iqbal ZA, Kalra H, Guliani A, Singh AK, Budhraja A, Jain G, Mehrotra B, Mangla L, Kumar A, Purohit V, Chinda M. An Indian Perspective on the Use of Fluticasone/Formoterol in Asthma and Chronic Obstructive Pulmonary Disease Patients. Indian J Respir Care 2021; 10 (2):196-200.

DOI: 10.4103/ijrc.ijrc_134_20

License: CC BY-NC-SA 4.0

Published Online: 06-12-2022

Copyright Statement:  Copyright © 2021; Indian Journal of Respiratory Care.


Despite rapidly evolving health-care systems, India continues to have a high disease burden for asthma and chronic obstructive pulmonary disease (COPD). The Asia-Pacific Asthma Insights and Management survey clearly revealed that asthma management remains very poor with worst clinical outcomes in India. Potent inhaled corticosteroids (ICS) and quick onset of long-acting beta2-agonist (LABA) are considered to be optimal dual therapy for management of asthma and COPD. Fluticasone's long-term action against inflammation and formoterol's rapid long-term bronchodilator action are vital clinical attributes for optimal asthma maintenance treatment. In an 8- and 12-week trial, dual therapy of fluticasone and formoterol (FF) reported lung function improvements and better control of asthma than its monotherapy. A large clinical study revealed mild adverse events of dual FF than other dual ICS-LABA combinations. Recent pooled analysis of asthma showed that fluticasone shares a lower risk of pneumonia in asthma. Dual ICS-LABA therapies are preferred in COPD individuals with history of exacerbations. Numerous clinical studies showed significant efficacy, dose adjustments/switching, and safety outcomes with dual FF therapy in asthma and COPD. Dual FF inhaler therapy ensures highly potent anti-inflammatory activity and sustained bronchodilation, thus making this a preferred combination in terms of efficacy, safety, and patient adherence in asthma and COPD. This present review focuses on the combination therapyof formoterol and fluticasone for managing asthma and COPD.

  1. Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India 2015;32:S3-42.
  2. Jain N, Satish K, Abhyankar N, Velayudhan N, Gurunathan J. Repeated exacerbation of asthma: An intrinsic phenotype of uncontrolled asthma. Lung India 2019;36:131-8.
  3. Salvi SS, Apte KK, Dhar R, Shetty P, Faruqi RA, Thompson PJ, et al. Asthma Insights and Management in India: Lessons Learnt from the Asia Pacific-Asthma Insights and Management (AP-AIM) Study. J Assoc Physicians India 2015;63:36-43.
  4. GINA Main Report-Global Initiative for Asthma. Available from: [Last accessed on 2020 Oct 16].
  5. Papi A, Price D, Sastre J, Kaiser K, Lomax M, McIver T, et al. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. Respir Med 2015;109:208-17.
  6. McKeage K. Fluticasone propionate/formoterol fumarate: A review of its use in persistent asthma. Drugs 2013;73:195-206.
  7. Rajesh V, Augustine J, Divya R, Cleetus M. Inhaled formoterol-fluticasone single inhaler therapy in asthma: Real-world efficacy, budget impact, and potential to improve adherence. Can Respir J 2020;2020:8631316.
  8. Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, Callan C, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017;5:1378-87.e5.
  9. Wan Yau Ming S, Haughney J, Small I, Wolfe S, Hamill J, Gruffydd-Jones K, et al. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation. Respir Med 2017;129:199-206.
  10. Dissanayake S, Grothe B, Kaiser K. Fluticasone/formoterol: A new single-aerosol combination therapy for patients with asthma. Respir Med 2012;106 Suppl 1:S20-8.
  11. Papi A, Mansur AH, Pertseva T, Kaiser K, McIver T, Grothe B, et al. Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. J Aerosol Med Pulm Drug Deliv 2016;29:346-61.
  12. Cukier A, Jacob CM, Rosario Filho NA, Fiterman J, Vianna EO, Hetzel JL, et al. Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma. Respir Med 2013;107:1330-8.
  13. Ghoshal A, Waghray P, Dsouza G, Saluja M, Agarwal M, Goyal A, et al. Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India. Pulm Pharmacol Ther 2020;60:101869.
  14. GOLD Guidelines for COPD. Available from: [Last accessed on 2020 Oct 16].
  15. Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint recommendations of Indian Chest Society and National College of Chest Physicians (India). Indian J Chest Dis Allied Sci 2014;56 Spec No:5-54.
  16. Koul PA. Chronic obstructive pulmonary disease: Indian guidelines and the road ahead. Lung India 2013;30:175-7.
  17. Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: What is their role in therapy? Int J Chron Obstruct Pulmon Dis 2018;13:2587-601.
  18. Kumar S, Madhuri G, Wilson A, George T. Study of prescribing pattern of drugs in chronic obstructive pulmonary disease in tertiary care teaching hospital. Indian J Pharm Pract 2019;12:161-6.
  19. Srikala TS. V Saika, Babu KR, Eswaraiah MC. Assessment of prescription pattern among COPD patients in departments of General Medicine Ward and Pulmonology in Tertiary Care Hospitals of Khammam Region. Int J Res Pharm Sci 2020;11:1798-806.
  20. Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, et al. Fluticasone propionate/formoterol for COPD management: A randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2017;12:1961-71.
  21. Altaf M, Zubedi AM, Nazneen F, Kareemulla S, Ali SA, Aleemuddin NM, et al. Cost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India. Perspect Clin Res 2015;6:150-8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.